Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • IT / Health Venture
    • Medicover to invest Rs...

    Medicover to invest Rs 660 crore in India for 50 fertility clinics

    Written by savita thakur thakur Published On 2016-04-02T11:24:54+05:30  |  Updated On 2 April 2016 11:24 AM IST
    Medicover to invest Rs 660 crore in India for 50 fertility clinics

    New Delhi : Europe's leading healthcare provider Medicover plans to invest USD 100 million (over Rs 660 crore) to set up 50 fertility clinics in India over the next three years.


    The company, which started its operations in Poland some 20 years ago, plans to set up clinics in the Delhi/NCR region in the first phase followed by central and western parts of the country.


    "We are currently present in geographies like the UK, Poland, Ukraine and now plan to invest USD 100 million in India over the next three fiscals to set up 50 fertility clinics," Medicover Division Chief Executive Officer John Stubbington told .


    The family-owned enterprise aims to fund the USD 100 million expansion in India through internal accruals.


    Initially, the company plans to come up with four clinics in the Delhi/NCR in the next two months with plans to have 10 such outlets in the country by the end of the year.


    "After Delhi NCR, we plan to expand in other northern states like Punjab, Haryana and then move on to locations in central India. We also plan to enter western parts of the country at a later stage," Medicover Healthcare Managing Director and CEO Gaurav Malhotra said.


    Elaborating on the growth prospects in the Indian market, he added that around 30 million couples in India suffer from fertility issues and there is lack of quality facilities to deal with the condition in the country.


    "Around 90 per cent of the couples who come to us end up with babies. We have relentless focus on quality and we want to bring the same European medical standards to India," Stubbington said.


    The company will also issue DNA certificate to each couple in country after the completion of the process. It also plans to constitute a board which would look after complaints, if any.


    "We have already hired a team in India including IVF specialists and plans to leverage the knowledge of doctors based in Europe to train manpower in India," Malhotra said.


    Globally the group employs around 12,500 people across 15 countries. It posted revenues of 480 million euros last year and expect to close the current year at 600 million euros. MSS MR

    50 fertility clinicsGaurav MalhotraIVFJohn StubbingtonMedicover
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok